Ginkgo Bioworks Holdings Inc (DNA) 13F Holders & Ownership Data (186 Funds, Q2 2026)

DNA ranks #3198 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

DNA is a disclosed holding of Andreas Halvorsen (Viking Global Investors), one of the tracked superinvestors on AlphaSMO — it makes up 0.1% of that fund's own 13F portfolio.

186 institutions disclose a position in DNA, but none treat it as a major bet — even Anchorage Capital Group, L.L.C., its most concentrated holder, allocates just 3.8% of its own portfolio to it.

Forbes J M & Co LLP has added to its DNA position for two straight quarters, increasing it by $6.2M to reach $12.5M today.

Essential Partners LLC has trimmed its DNA position for two straight quarters, cutting it by $17.7K while still holding $975.0.

DNA is down 12.7% today, but institutions show net buying of $60.5M this quarter — a divergence between today's price move and the underlying institutional flow.

DNA reported a net loss of $290.8M over the trailing twelve months.

• Not yet profitable — net loss of $290.8M over the trailing twelve months
• Revenue declined 46.8% year over year
• Net income improved year over year, from -$315.2M to -$290.8M
• Operating cash flow was negative, using $171.1M in cash
• Current ratio of 4.92x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.20x equity — within a conventional range